Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1154) 1154
Newspaper Article (297) 297
Publication (78) 78
Patent (38) 38
Conference Proceeding (16) 16
Dissertation (12) 12
Book / eBook (10) 10
Book Review (10) 10
Book Chapter (6) 6
Magazine Article (4) 4
Report (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (552) 552
male (358) 358
index medicus (351) 351
female (329) 329
cardiac & cardiovascular systems (288) 288
middle aged (253) 253
heart failure (230) 230
aged (224) 224
cardiovascular (169) 169
mortality (160) 160
adult (130) 130
heart failure - drug therapy (126) 126
treatment outcome (118) 118
medicine, general & internal (117) 117
hypertension (113) 113
animals (112) 112
risk factors (96) 96
care and treatment (88) 88
double-blind method (88) 88
drug therapy (86) 86
blood pressure (81) 81
heart failure - physiopathology (80) 80
pharmacology & pharmacy (80) 80
peripheral vascular disease (78) 78
chronic disease (75) 75
myocardial-infarction (74) 74
prospective studies (72) 72
abridged index medicus (71) 71
hypertension - drug therapy (63) 63
aged, 80 and over (62) 62
heart failure - mortality (62) 62
rats (62) 62
research (62) 62
follow-up studies (60) 60
risk (60) 60
cardiac patients (59) 59
cardiovascular disease (58) 58
clinical trials (57) 57
analysis (55) 55
blood pressure - drug effects (55) 55
adrenergic beta-antagonists - therapeutic use (54) 54
disease (54) 54
trial (54) 54
myocardial infarction (52) 52
survival (49) 49
time factors (49) 49
heart failure - diagnosis (48) 48
diabetes (46) 46
prognosis (46) 46
therapy (46) 46
blood-pressure (45) 45
heart failure - therapy (45) 45
antihypertensive agents - therapeutic use (44) 44
cardiovascular diseases (43) 43
double-blind (43) 43
angiotensin-converting enzyme inhibitors - therapeutic use (42) 42
australia (42) 42
hypertension - physiopathology (41) 41
management (41) 41
drug therapy, combination (40) 40
heart attacks (40) 40
fibrosis (38) 38
morbidity (38) 38
hospitalization (37) 37
outcomes (37) 37
carvedilol (36) 36
dose-response relationship, drug (36) 36
heart-failure (36) 36
left-ventricular dysfunction (36) 36
rats, sprague-dawley (36) 36
diagnosis (35) 35
kidney - innervation (35) 35
patient outcomes (35) 35
heart (34) 34
prevention (34) 34
echocardiography (33) 33
health aspects (33) 33
studies (33) 33
association (32) 32
cardiology (32) 32
internal medicine (32) 32
randomized-trial (32) 32
acute myocardial-infarction (31) 31
blood pressure - physiology (31) 31
medicine & public health (31) 31
metaanalysis (31) 31
randomized controlled trials as topic (31) 31
electrocardiography (30) 30
guidelines (30) 30
hiv infections - drug therapy (30) 30
severity of illness index (30) 30
angiotensin (29) 29
clinical medicine (29) 29
incidence (29) 29
medical research (29) 29
resistant hypertension (29) 29
spironolactone - analogs & derivatives (29) 29
aldosterone (28) 28
physiology (28) 28
spironolactone (28) 28
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Robarts - Stacks (2) 2
UTL at Downsview - May be requested (2) 2
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Engineering & Comp. Sci. - Stacks (1) 1
Gerstein Science - Stacks (1) 1
Online Resources - Online (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1508) 1508
German (13) 13
Bulgarian (7) 7
French (6) 6
Portuguese (5) 5
Spanish (4) 4
Dutch (2) 2
Czech (1) 1
Italian (1) 1
Macedonian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
by Ridker, Paul M and Everett, Brendan M and Thuren, Tom and MacFadyen, Jean G and Chang, William H and Ballantyne, Christie and Fonseca, Francisco and Nicolau, Jose and Koenig, Wolfgang and Anker, Stefan D and Kastelein, John J.P and Cornel, Jan H and Pais, Prem and Pella, Daniel and Genest, Jacques and Cifkova, Renata and Lorenzatti, Alberto and Forster, Tamas and Kobalava, Zhanna and Vida-Simiti, Luminita and Flather, Marcus and Shimokawa, Hiroaki and Ogawa, Hisao and Dellborg, Mikael and Rossi, Paulo R.F and Troquay, Roland P.T and Libby, Peter and Glynn, Robert J and CANTOS Trial Grp and CANTOS Trial Group and Sahlgrenska akademin and Institute of Medicine and Göteborgs universitet and Gothenburg University and Sahlgrenska Academy and Institutionen för medicin
The New England Journal of Medicine, ISSN 0028-4793, 09/2017, Volume 377, Issue 12, pp. 1119 - 1131
Patients with myocardial infarction and a high-sensitivity CRP level of 2 mg or more per liter were assigned to one of three canakinumab doses or placebo. The... 
C-REACTIVE PROTEIN | MEDICINE, GENERAL & INTERNAL | HEART-DISEASE | MYOCARDIAL-INFARCTION | STATIN THERAPY | CLONAL HEMATOPOIESIS | INFLAMMATION | CARDIOVASCULAR-DISEASE | INTERLEUKIN-1-BETA INHIBITION | RISK | CORONARY-ARTERY-DISEASE | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Secondary Prevention | Infection - etiology | Incidence | Dose-Response Relationship, Drug | Anti-Inflammatory Agents - adverse effects | C-Reactive Protein - metabolism | Lipids - blood | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Anti-Inflammatory Agents - administration & dosage | Female | Neutropenia - chemically induced | Interleukin-1beta - antagonists & inhibitors | Stroke - prevention & control | Atherosclerosis - drug therapy | Double-Blind Method | Interleukin-1beta - immunology | Atherosclerosis - blood | Myocardial Infarction - drug therapy | Antibodies, Monoclonal - administration & dosage | Aged | Myocardial Infarction - prevention & control | Myocardial infarction | Cerebral infarction | Stroke | Heart attacks | C-reactive protein | Cytokines | Clinical trials | Cardiovascular disease | Innate immunity | Inflammation | Angina | Angina pectoris | Thrombosis | Cholesterol | Disease prevention | Proteins | Arteriosclerosis | Atherosclerosis | Cardiovascular diseases | Health risk assessment | Drug therapy | Drug dosages | Klinisk medicin | Clinical Medicine
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease
by Yusuf, Salim and Bosch, Jackie and Dagenais, Gilles and Zhu, Jun and Xavier, Denis and Liu, Lisheng and Pais, Prem and López-Jaramillo, Patricio and Leiter, Lawrence A and Dans, Antonio and Avezum, Alvaro and Piegas, Leopoldo S and Parkhomenko, Alexander and Keltai, Matyas and Keltai, Katalin and Sliwa, Karen and Peters, Ron J.G and Held, Claes and Chazova, Irina and Yusoff, Khalid and Lewis, Basil S and Jansky, Petr and Khunti, Kamlesh and Toff, William D and Reid, Christopher M and Varigos, John and Sanchez-Vallejo, Gregorio and McKelvie, Robert and Pogue, Janice and Jung, Hyejung and Gao, Peggy and Diaz, Rafael and Lonn, Eva and HOPE-3 Investigators
The New England Journal of Medicine, ISSN 0028-4793, 05/2016, Volume 374, Issue 21, pp. 2021 - 2031
In one comparison from a 2-by-2 factorial trial, 12,705 persons at intermediate cardiovascular risk were assigned to either rosuvastatin or placebo. At 5.6... 
PREVENTION | MEDICINE, GENERAL & INTERNAL | INTERHEART | MYOCARDIAL-INFARCTION | 52 COUNTRIES | CATARACT | Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage | Cardiovascular Diseases - ethnology | Double-Blind Method | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Risk Factors | Rosuvastatin Calcium - adverse effects | Male | Hypercholesterolemia - drug therapy | Rosuvastatin Calcium - administration & dosage | Medication Adherence | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Cardiovascular Diseases - mortality | Cholesterol, LDL - blood | Female | Aged | Care and treatment | Usage | Clinical trials | Rosuvastatin | Dosage and administration | Cardiovascular diseases | Risk factors | Cholesterol | Hypertension | Myocardial infarction | Cerebral infarction | C-reactive protein | Diabetes mellitus | Cardiovascular disease | Lipids | Inflammation | Low density lipoprotein | Disease prevention | Surgery | Blood pressure | Health risk assessment | Drug therapy | Heart diseases | Statins
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease
by Lonn, Eva M and Bosch, Jackie and López-Jaramillo, Patricio and Zhu, Jun and Liu, Lisheng and Pais, Prem and Diaz, Rafael and Xavier, Denis and Sliwa, Karen and Dans, Antonio and Avezum, Alvaro and Piegas, Leopoldo S and Keltai, Katalin and Keltai, Matyas and Chazova, Irina and Peters, Ron J.G and Held, Claes and Yusoff, Khalid and Lewis, Basil S and Jansky, Petr and Parkhomenko, Alexander and Khunti, Kamlesh and Toff, William D and Reid, Christopher M and Varigos, John and Leiter, Lawrence A and Molina, Dora I and McKelvie, Robert and Pogue, Janice and Wilkinson, Joanne and Jung, Hyejung and Dagenais, Gilles and Yusuf, Salim and HOPE-3 Investigators and Medicinska fakulteten and Medicinska och farmaceutiska vetenskapsområdet and Kardiologi and Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm and Uppsala universitet and Institutionen för medicinska vetenskaper and Uppsala kliniska forskningscentrum (UCR)
The New England Journal of Medicine, ISSN 0028-4793, 05/2016, Volume 374, Issue 21, pp. 2009 - 2020
In one comparison from a 2-by-2 factorial trial, over 12,000 participants with a mean baseline blood pressure of 138/82 mm Hg were assigned to candesartan plus... 
DIABETES-MELLITUS | MEDICINE, GENERAL & INTERNAL | METAANALYSIS | EVENTS | RANDOMIZED-TRIALS | REDUCTION | REGIONS | PROSPECTIVELY-DESIGNED OVERVIEWS | HYPERTENSION | REGIMENS | Blood Pressure | Double-Blind Method | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Risk Factors | Kaplan-Meier Estimate | Antihypertensive Agents - administration & dosage | Hypertension - drug therapy | Male | Hydrochlorothiazide - administration & dosage | Hypotension - chemically induced | Antihypertensive Agents - adverse effects | Incidence | Benzimidazoles - administration & dosage | Tetrazoles - administration & dosage | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Aged | Drug Therapy, Combination | Care and treatment | Usage | Candesartan | Clinical trials | Dosage and administration | Cardiovascular diseases | Risk factors | Hypertension | Myocardial infarction | Cerebral infarction | Stroke | Risk groups | Cardiovascular disease | Hydrochlorothiazide | Cholesterol | Blood pressure | Health risk assessment | Drug therapy | Heart diseases | Medical and Health Sciences | Medicin och hälsovetenskap
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights